OncoMatch/Clinical Trials/NCT06960577
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Is NCT06960577 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for urinary bladder neoplasms.
Treatment: Durvalumab · Methotrexate · Vinblastine · Doxorubicin · Cisplatin · Durvalumab · Gemcitabine · Cisplatin — The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage T2N0M0, T2N1M0, T3N0M0, T3N1M0, T4AN0M0, T4AN1M0, T1N1M0 (TNM)
clinical tumour stage T2-T4aN0/1M0 or T1N1M0; Evidence of lymph node (N2-N3) or metastatic (M1) disease [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic chemotherapy
Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer
Cannot have received: immunotherapy
Exception: excluding Bacillus Calmette-Guérin
Prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD 1, anti-PD L1 and anti-PD-L2 antibodies, excluding Bacillus Calmette-Guérin
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify